PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 28, 2026SHILAP Revista de lepidopterología0 citationsOpen Access

Complications and risk factors for removal of totally implanted venous access ports in patients receiving systemic anticancer treatment

View Full Paper
KRKatarzyna M. RomańczukMedical University of WarsawMLMaciej LatosMedical University of WarsawASAntonina SpalińskaUniversity of Warsaw

Key Points

  • This research evaluates TIVAP-related complications and identifies risk factors for port removal in oncology patients.
  • Single-center retrospective study involving 393 patients with TIVAP implantation from February 2024 to November 2025.
  • Data obtained from electronic medical records; analyzed various patient, treatment, and device-related variables.
  • Primary outcome assessed was port-related complications and time to removal using multivariable Cox proportional hazards regression.
  • Port-related complications occurred in 42 patients (10.7%), with infectious complications most common (20/42).
  • Port removal due to complications required in 31 patients (7.9%).
  • Prior administration of systemic anticancer treatment was associated with a higher hazard of port removal (HR = 2.16; 95% CI 1.04–4.49; p = 0.039).

Abstract

INTRODUCTION: Totally implantable venous access ports (TIVAPs) are widely used in oncology for administering systemic anticancer treatment, but they may be associated with infectious, mechanical, thrombotic, and local complications. This study aimed to evaluate the incidence and spectrum of TIVAP-related complications and iden­tify factors associated with port removal in hospitalized oncology patients. MATERIAL AND METHODS: This single-center retrospective study included 393 patients who underwent TIVAP implan­tation between February 2024 and November 2025. Data were obtained from electronic medical records. Patient-, treatment-, and device-related variables were analyzed. The primary outcome was the occurrence of port-related complications, with time to removal assessed using multivariable Cox proportional hazards regression. RESULTS: A total of 393 patients were analyzed, with a median follow-up of 161 days (IQR: 74–251). Port-related complications occurred in 42 patients (10.7%), with infectious complications being the most common (20/42). Port removal due to complications was required in 31 patients (7.9%). In multivariable time-to-event analysis, administration of systemic anticancer treatment prior to port implantation was associated with higher hazard of port removal due to complications (HR = 2.16; 95% CI 1.04–4.49; p = 0.039). No other clinical factors showed a significant association. CONCLUSIONS: TIVAP-related complications occurred in approximately 10.7% of patients, with infectious complica­tions being the most frequent. This underscores the importance of vigilant monitoring and standardized infection prevention practice in patients with implanted venous ports. Prior administration of systemic anticancer treatment before port implantation was associated with a higher hazard of port removal, suggesting that the timing of port insertion relative to systemic therapy may influence device durability. These findings warrant validation in further prospective studies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Romańczuk et al. (2026) studied this question.

synapsesocial.com/papers/69f04e9b727298f751e72935https://doi.org/10.5603/ocp.111163
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Early and late complications and predictors of port removal in cancer patients with totally implantable venous access devices (TIVADs): a single-center retrospective study2025
  2. 2Safety and clinical impact of totally implantable venous access ports during trabectedin therapy in advanced L-type sarcomas: A multicenter SEPSaC-01 analysis.2026
  3. 3Effects of totally implantable venous access ports on complications and quality of life in gastrointestinal cancer chemotherapy2025 · 3 citations
  4. 4Post-Treatment Trajectories of Retained Totally Implantable Venous Access Ports After Anticancer Therapy: A Conditional Landmark Cohort Study2026
  5. 5Safety and Efficacy of Standardized Internal Jugular Vein Totally Implantable Venous Access Ports: Focus on Complication Profile and Risk Factors2025